Information Provided By:
Fly News Breaks for December 18, 2019
Dec 18, 2019 | 07:15 EDT
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Adamas Pharmaceuticals to $10 from $30 after ADS-5102 did not significantly impact secondary walking measures at either dose in the INROADS study. The analyst removed all contribution from ADS-5102 in the multiple sclerosis indication from his model. However, he believes Adamas is undervalued at the current share price and thus reiterates a Buy rating.
News For ADMS From the Last 2 Days
There are no results for your query ADMS